Your browser doesn't support javascript.
loading
Early pregnancy HbA1c as the first screening test for gestational diabetes: results from three prospective cohorts.
Saravanan, Ponnusamy; Deepa, Mohan; Ahmed, Zain; Ram, Uma; Surapaneni, Tarakeswari; Kallur, Sailaja Devi; Desari, Papa; Suresh, Seshadri; Anjana, Ranjit Mohan; Hannah, Wesley; Shivashri, Chockalingam; Hemavathy, Saite; Sukumar, Nithya; Kosgei, Wycliffe K; Christoffersen-Deb, Astrid; Kibet, Vincent; Hector, John N; Anusu, Gertrude; Stallard, Nigel; Ghebremichael-Weldeselassie, Yonas; Waugh, Norman; Pastakia, Sonak D; Mohan, Viswanathan.
Afiliação
  • Saravanan P; Warwick Applied Health, Warwick Medical School, University of Warwick, Coventry, UK; Warwick Centre for Global Health, University of Warwick, Coventry, UK; Department of Diabetes, Endocrinology and Metabolism, George Eliot Hospital, Nuneaton, UK. Electronic address: p.saravanan@warwick.ac.uk.
  • Deepa M; Department of Epidemiology, Madras Diabetes Research Foundation, Chennai, India.
  • Ahmed Z; Warwick Applied Health, Warwick Medical School, University of Warwick, Coventry, UK.
  • Ram U; Seethapathy Clinic and Hospital, Chennai, India; Fetal Care Research Foundation, Chennai, India.
  • Surapaneni T; Fernandez Hospitals, Hyderabad, India.
  • Kallur SD; Fernandez Hospitals, Hyderabad, India.
  • Desari P; Obstetrics and Gynaecology, Jawaharlal Institute of Post Graduate Medical Education, Puducherry, India.
  • Suresh S; Fetal Care Research Foundation, Chennai, India; Mediscan Systems, Chennai, India.
  • Anjana RM; Department of Diabetology, Madras Diabetes Research Foundation, Chennai, India; Department of Diabetology, Dr Mohan's Diabetes Specialities Centre, Chennai, India.
  • Hannah W; Department of Epidemiology, Madras Diabetes Research Foundation, Chennai, India; School of Medicine, Deakin University, Melbourne, VIC, Australia.
  • Shivashri C; Warwick Applied Health, Warwick Medical School, University of Warwick, Coventry, UK; Department of Epidemiology, Madras Diabetes Research Foundation, Chennai, India.
  • Hemavathy S; Department of Epidemiology, Madras Diabetes Research Foundation, Chennai, India; University of Madras, Chennai, India.
  • Sukumar N; Warwick Applied Health, Warwick Medical School, University of Warwick, Coventry, UK; Department of Diabetes, Endocrinology and Metabolism, George Eliot Hospital, Nuneaton, UK.
  • Kosgei WK; Moi Teaching and Referral Hospital, Eldoret, Kenya.
  • Christoffersen-Deb A; Moi Teaching and Referral Hospital, Eldoret, Kenya; Department of Obstetrics and Gynaecology, University of Toronto, ON, Canada; Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, BC, Canada.
  • Kibet V; Moi Teaching and Referral Hospital, Eldoret, Kenya.
  • Hector JN; Moi Teaching and Referral Hospital, Eldoret, Kenya.
  • Anusu G; Moi Teaching and Referral Hospital, Eldoret, Kenya.
  • Stallard N; Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.
  • Ghebremichael-Weldeselassie Y; Warwick Applied Health, Warwick Medical School, University of Warwick, Coventry, UK; School of Mathematics and Statistics, The Open University, Milton Keynes, UK.
  • Waugh N; Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.
  • Pastakia SD; Moi Teaching and Referral Hospital, Eldoret, Kenya; Purdue University College of Pharmacy, Center for Health Equity and Innovation, West Lafayette, IN, USA.
  • Mohan V; Department of Diabetology, Madras Diabetes Research Foundation, Chennai, India; Department of Diabetology, Dr Mohan's Diabetes Specialities Centre, Chennai, India.
Article em En | MEDLINE | ID: mdl-38936371
ABSTRACT

BACKGROUND:

More than 90% of gestational diabetes cases are estimated to occur in low-income and middle-income countries (LMICs). Most current guidelines recommend an oral glucose tolerance test (OGTT) at 24-28 weeks of gestation. The OGTT is burdensome, especially in LMICs, resulting in a high proportion of women not being screened. We aimed to develop a simple and effective screening strategy for gestational diabetes.

METHODS:

STRiDE, a prospective cohort study, was set up in seven centres in south India and seven centres in western Kenya, and included pregnant women aged 18-50 years of age and at less than 16 weeks of gestation (<20 weeks in Kenya), confirmed by dating ultrasound. We assessed the efficacy of early pregnancy HbA1c (venous and capillary point-of-care), either alone or as part of a composite risk score with age, BMI, and family history of diabetes, in predicting gestational diabetes at 24-28 weeks of gestation, in two LMICs (India and Kenya) and in a UK multi-ethnic population from the PRiDE study. A key secondary outcome was to assess whether an early pregnancy composite risk score can reduce the need for OGTTs. Gestational diabetes was diagnosed using current WHO criteria.

FINDINGS:

Between Feb 15, 2016, Dec 13, 2019, we enrolled 3070 participants in India and 4104 in Kenya. 4320 participants were included from the PRiDE cohort. Gestational diabetes prevalence by OGTT at 24-28 weeks was 19·2% in India, 3·0% in Kenya, and 14·5% in the UK. Early pregnancy HbA1c was independently associated with incidence of gestational diabetes at 24-28 weeks of gestation. Adjusted risk ratios were 1·60 (95% CI 1·19-2·16) in India, 3·49 (2·8-4·34) in Kenya, and 4·72 (3·82-5·82) in the UK. Composite risk score models that combined venous or point-of-care HbA1c with age, BMI, and family history of diabetes best predicted testing positive for gestational diabetes. A population-specific, two-threshold screening strategy of rule-in and rule-out gestational diabetes using early pregnancy composite risk score could reduce the requirement of OGTTs by 50-64%. For the HbA1c-alone model, the thresholds were 5·4% (rule in) and 4·9% (rule out) in India, 6·0% (rule in) and 5·2% (rule out) in Kenya, and 5·6% (rule in) and 5·2% (rule out) in the UK.

INTERPRETATION:

Early pregnancy HbA1c offers a simple screening test for gestational diabetes, allowing those at highest risk to receive early intervention and greatly reduce the need for OGTTs. This can also be carried out using point-of-care HbA1c in LMICs.

FUNDING:

UK Medical Research Council and the Indian Department of Biotechnology.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Lancet Diabetes Endocrinol Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Lancet Diabetes Endocrinol Ano de publicação: 2024 Tipo de documento: Article